News

One in 10 people with atopic dermatitis, the most common type of eczema, have symptoms on their feet. These quick facts can help you manage it.
There are many possible causes of red spots on the feet, including injuries, insect bites, irritations, and infections. ... Atopic dermatitis, or eczema, is an inflammation of the skin.
Dupixent ® (dupilumab) US label updated with data further supporting use in atopic dermatitis with moderate-to-severe hand and foot involvement. News release. Regeneron Pharmaceuticals, Inc ...
NEW ORLEANS — Patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile, according to phase 3 study results ...
Red, itchy blisters on your hands, fingers, & feet could mean dyshidrotic eczema. Find out what causes this skin condition and how to treat it. ... such as contact and atopic dermatitis.
Dupixent for atopic dermatitis has received a label update from the FDA adding phase 3 efficacy and safety data, Regeneron and Sanofi announced in a press release. The updated data for Dupixent ...
In very young children, atopic dermatitis can develop on the scalp and face, especially on the cheeks, as well as on other parts of the body, including the hands and feet. It does not, however ...
Atopic dermatitis is a very common skin disease found in both adults and children. In fact, up to 10 to 20 percent of the population at some point suffers from atopic dermatitis.
Dyshidrotic eczema is a type of dermatitis that affects the hands and feet. Learn about the signs, risk factors, treatment, and prevention options in this science-backed article.
Atopic dermatitis is a form of dermatitis. [ 10 ] eczema A group of inflammatory skin conditions that can cause dry, itchy skin along with rashes, scaly patches, blisters, and skin infections.
Phase 3 trial showed more than twice as many patients treated with Dupixent achieved clear or almost clear skin and nearly four times as many had improvement in itch, compared with placebo “We ...